跳至主要内容
临床试验/NCT03440255
NCT03440255已完成不适用

Transcutaneous Vagus Nerve Stimulation (TaVNS) in Private Healthcare Center: An Open-Label, Non-Randomized Feasibility Study Targeting Anxiety, Chronic Pain and Irritable Bowel Syndrome

Kinesis Health Associates2 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2017年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
11
试验地点
2
主要终点
Change from baseline generalized anxiety disorder severity

研究概览

简要总结

This non-randomized, open-label study has the objective to study the effects and feasibility of Transauricular Vagus Nerve Stimulation (TaVNS) for patients suffering from Generalized Anxiety Disorder (GAD), Chronic Pain (CP) and Irritable Bowel Syndrome (IBS) in a private healthcare centre.

详细描述

The effects of TaVNS on GAD, CP and IBS. Participants were investigated during a 4-week period and a 2-month follow-up. Groups (GAD, CP, IBS) were assessed using questionnaires: Anxiety (Generalized Anxiety Disorder GAD-7); CP (Brief Pain Inventory Short Form Questionnaire) and IBS (Irritable Bowel Syndrome Severity Scoring System). TaVNS was performed using a standard transcutaneous electrical nerve stimulation (TENS) device and ear clip electrodes plugged into the concha area of the left ear. All participants received a bi-weekly 30 minutes stimulation (8 sessions). We defined three different TaVNS parameters for each group in hertz (Hz) and microsecond (µs), (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age range 20-65 years old
  • Patient suffering from either Generalized Anxiety Disorder, Chronic Pain scoring and Irritable Bowel Syndrome from moderate
  • Patients meet the scoring standard questionnaires: mild to severe
  • Patient can understand and answer the questions
  • Patient exhibits symptoms for at least six months

排除标准

  • Reading difficulties
  • Diagnosed left ear lesion
  • Measured blood pressure under 100/60 with or without anti-high blood pressure medicine
  • Active implant such as cochlear implant
  • Wounds and skin disease in the left ear
  • Recent head trauma or concussion
  • Cardiac pacemaker
  • Severe alcoholism
  • Left cervical vagotomy
  • Cholinergic or B blocking medicine
  • Recreative drugs
  • Diagnosed concomitant psychiatric comorbidity
  • Diagnosed concomitant personal disorders
  • Diagnosed pregnancy
  • Diagnosed concomitant severe neurological or medical diseases such as neoplasms in activity, neurodegenerative diseases and chronic infectious diseases uncompensated

研究组 & 干预措施

Transcutaneous Vagus Nerve Stimulation

Experimental

TaVNS 8 sessions, 30 min, 4 weeks GAD: 20 Hertz (Hz) - 80 microseconds (µs) CP: 5Hz-200µs IBS: 3Hz-250µs

干预措施: Transcutaneous Vagus Nerve Stimulation (Device)

结局指标

主要结局

Change from baseline generalized anxiety disorder severity

时间窗: baseline, 4-week and 2-month follow-up

To assess the response effect of the TaVNS on the severity of anxiety disorders measured by the 21 items self-administered Generalized Anxiety Disorder GAD-7 questionnaire, where scoring scores of 5, 10 and 15 represent cut-off points for mild, moderate and severe anxiety. A response will be considered as a reduced cut-off point from baseline.

Change from baseline pain severity and pain interference

时间窗: baseline, 4-week and 2-month follow-up

To assess the response effect of the TaVNS on the severity of pain and the impact of this pain on daily functioning (Interference) measured by the 9 items self-administered Brief Pain Inventory (Short Form) questionnaire; from 0 (no pain) to 10 (worst pain), ratings from 1 to 4 corresponded to mild pain, 5 to 6 to moderate pain, and 7 to 10 to severe pain with cut-off points being 4 and 6. Scoring pain severity is the mean of the total pain score out of 10. Interference from 0 (no interference) to 10 (completely interferes), rating mild (\<=5), moderate (6-7), and severe (\>= 8) with cut-off points being 5 and 7. Scoring the interference severity is the mean of the total Interference score out of 10. A response will be considered as a reduced cut-off point from baseline.

Change from baseline irritable bowels syndrome severity

时间窗: baseline, 4-week and 2-month follow-up

To assess the response effect of the TaVNS on the severity of irritable bowel syndrome measured by the self-administered Irritable Bowel Syndrome Severity Scoring System (IBS-SSS), where the maximum achievable score is 500. Mild, moderate and severe categories were indicated by scores of 75 to 175, 175 to 300 and \> 300 respectively, with cut-off points being 175 and 300. A response will be considered as a reduced cut-off point from baseline.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Pascal J.D. Grolaux, DO

Principal Investigator

Kinesis Health Associates

研究点 (2)

Loading locations...

相似试验